Neurotech International (ASX:NTI) Ending Cash Position: A$6.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neurotech International Ending Cash Position?

Neurotech International ASX:NTI -6.25% Ending Cash Position is A$6.34 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Neurotech International's Ending Cash Position for the quarter that ended in Dec. 2025 was A$6.34 Mil.

Neurotech International's quarterly Ending Cash Position declined from Dec. 2024 (A$5.96 Mil) to Jun. 2025 (A$3.03 Mil) but then increased from Jun. 2025 (A$3.03 Mil) to Dec. 2025 (A$6.34 Mil).

Neurotech International's annual Ending Cash Position increased from Jun. 2023 (A$5.03 Mil) to Jun. 2024 (A$11.63 Mil) but then declined from Jun. 2024 (A$11.63 Mil) to Jun. 2025 (A$3.03 Mil).

Neurotech International Ending Cash Position Related Terms

Neurotech International Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Neurotech International's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International Ending Cash Position Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 4.83 1.90 5.03 11.63 3.03

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.48 11.63 5.96 3.03 6.34

Neurotech International Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neurotech International's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=11.625+-8.594
=3.03

Neurotech International's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.031+3.311
=6.34

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$6.34 Mil mean?
Neurotech International (ASX:NTI) has a Ending Cash Position of A$6.34 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neurotech International and its competitors.
Is Neurotech International's Ending Cash Position too high?
Neurotech International's current Ending Cash Position is A$6.34 Mil.
How does Neurotech International's Ending Cash Position compare to VRTX and REGN?
Neurotech International's Ending Cash Position of A$6.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neurotech International and its competitors. Neurotech International's current Ending Cash Position is A$6.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (ASX:NTI) has a current Ending Cash Position of A$6.34 Mil. The current Ending Cash Position is A$6.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Neurotech International (ASX:NTI), the current Ending Cash Position is A$6.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.